Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tarsus Pharmaceuticals (TARS) Depreciation & Amortization (CF) (2020 - 2025)

Tarsus Pharmaceuticals has reported Depreciation & Amortization (CF) over the past 6 years, most recently at $202000.0 for Q4 2025.

  • Quarterly results put Depreciation & Amortization (CF) at $202000.0 for Q4 2025, up 5.21% from a year ago — trailing twelve months through Dec 2025 was $822000.0 (up 18.79% YoY), and the annual figure for FY2025 was $855000.0, up 24.82%.
  • Depreciation & Amortization (CF) for Q4 2025 was $202000.0 at Tarsus Pharmaceuticals, up from $200000.0 in the prior quarter.
  • Over the last five years, Depreciation & Amortization (CF) for TARS hit a ceiling of $247000.0 in Q4 2023 and a floor of $40000.0 in Q4 2021.
  • Median Depreciation & Amortization (CF) over the past 5 years was $153500.0 (2021), compared with a mean of $144200.0.
  • Biggest five-year swings in Depreciation & Amortization (CF): skyrocketed 635.29% in 2021 and later tumbled 45.05% in 2024.
  • Tarsus Pharmaceuticals' Depreciation & Amortization (CF) stood at $40000.0 in 2021, then surged by 145.0% to $98000.0 in 2022, then soared by 152.04% to $247000.0 in 2023, then decreased by 22.27% to $192000.0 in 2024, then rose by 5.21% to $202000.0 in 2025.
  • The last three reported values for Depreciation & Amortization (CF) were $202000.0 (Q4 2025), $200000.0 (Q3 2025), and $200000.0 (Q2 2025) per Business Quant data.